Commentary · 2015
Review articlePublished 2016
Pharmacovigilance for Biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmacovigilance can be defined as the process of collection of safety and to a lesser extent efficacy information regarding pharmaceuticals that have already been launched in the market. It is possible that all toxicity has not been precisely identified before drugs obtain approval for marketing. In addition to relying in ad hoc toxicity reporting, formal studies may be conducted after drug approval to confirm safety (post-authorization safety study, PASS), as well as efficacy (post-authorization efficacy study, PAES). These studies are of paramount importance for biosimilars, due to their macromolecular and potential immunogenic nature. Biosimilars are used in many medical fields, including oncology and rheumatology. In order to guarantee the success of post-authorization studies, both health care professionals and patients are required to contribute by reporting adverse drug reactions (ADR). The European Union even urges patients to directly report ADR. Apart from physicians, pharmacists play an important role in pharmacovigilance, by keeping accurate records enabling the identification of a specific batch of a biosimilar to be linked to a particular ADR. Thus the principle of non-inter changeability of the prescribed product ought to be followed. PASS are mandatory for biosimilars at the responsibility of the market authorization holder. Implementation of rigorous pharmacovigilance policies will promote physicians' confidence in them, hopefully resulting in financial alleviation of Health Systems.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 30 Oct 2020
Biologics and Biosimilars:Safety and Pharmacovigilance
Conference abstract · 16 Oct 2020
Biologics and Biosimilars:Safety and Pharmacovigilance
Conference abstract
Biosimilars: Review of the safety issues and the current Pharmacovigilance methods
Mini review · 12 Sep 2025
Pharmacovigilance in the Era of Biologics and Biosimilars: Challenges and Solutions
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Advancing Patient Safety Through Modern Pharmacovigilance Practices
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Maria I Karampola”
- BylineArticles whose byline prints “Christos E Emmanouilides”

